$NUVB News

Nuvation Bio To Showcase New Outcomes Data From Its Pivotal TRUST-II Trial Of IBTROZI In Participants With Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio Inc. (NUVB) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript

Nuvation Bio Inc. (NUVB) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Nuvation Bio Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio to Participate in Upcoming Investor Conferences

RBC Capital Reiterates Outperform on Nuvation Bio, Maintains $20 Price Target

Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target

HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $17 Price Target

Nuvation Bio Q1 Earnings Call Highlights

Nuvation Bio Inc. Q1 2026 Earnings Call Summary

Nuvation Bio (NUVB) Q1 2026 Earnings Transcript

Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates

Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript

Nuvation Bio (NYSE:NUVB) Soars 22% After Earnings Beat Fueled by Strong Lung Cancer Drug Launch

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Nuvation Bio Q1 EPS $0.01, Inline, Sales $83.228M Beat $62.259M Estimate.

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth